Mirdametinib - CISMeF

Preferred Label : Mirdametinib;

NCIt synonyms : PD-0325901; MEK Inhibitor PD0325901;

NCIt definition : An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.;

UNII : 86K0J5AK6M;

CAS number : 391210-10-9;

Molecule name : PD 901;

Details

Origin ID

C52195;

UMLS CUI

C5447979;

Currated CISMeF NLP mapping
- Mirdametinib [SMS substance]
- mirdametinib [MeSH concept]
- mirdametinib [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- PD 0325901 [MeSH concept]
- mirdametinib [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- PD 0325901 [MeSH concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 [NCIt concept]
- Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients